The announcement of a collaboration with FluGen, especially in a high-demand sector like healthcare and vaccines, is likely to be viewed positively by investors. This partnership not only highlights Predictive Oncology's innovative approach in the healthcare sector but also promises potential growth and expansion in its product offerings. The positive market reaction is anticipated due to the increased investor confidence in Predictive Oncology's growth prospects and strategic partnerships.